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GRF (10-s-10-5 M) is shown to inhibit competitively the binding of [‘251]VIP to human and rat intestina1 
epithelial membranes. The affinity of GRF for VIP receptor is 700-800-times lower than that of VIP in 
both species. The order of affinity of different peptides is VIP > PHI > secretin > GRF in rat, and VIP 
> GRF > PHI > secretin in man. The important species specificity of VIP receptors in recognizing PHI 
and secretin does not occur in the case of GRF. GRF stimufates adenylate cyclase through its interaction 
with VIP receptors in rat and human membranes. However, while GRF behaves as a VIP agonist in human 
tissue, it is a partial agonist/antagonist of VIP in the rat. 
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1. INTRODUCTION 
The growth hormone releasing factor was 
recently isolated from a human pancreatic islet 
tumor [I]. The analysis of the sequence of this 44 
amino acids peptide revealed close structural 
similarities with the members of the so-called 
glucagon-VIP-secretin family [ 11. GRF possesses 
12, 9, 8, 6 and 5 amino acids in common with the 
porcine gut peptide, PHI 121, VIP 131, glucagon 
[4], secretin [S] and gastric inhibitory polypeptide, 
GIP [6], respectively. Peptides of this structural 
family exhibit great overlapping biological ac- 
Abbreviations: GRF, growth hormone releasing factor; 
PHI, porcine intestinal peptide having N-terminal 
histidine and C-termina1 isoleucine amide; VIP, vasoac- 
tive intestinal peptide 
tivities in various tissues [7]. This was shown to be 
due in some cases to cross-reactivity at the receptor 
level. In particular, we have shown that secretin 
and PHI are able to bind to VIP receptors with a 
low affinity [S]. 
The sequence homology between GRF and VIP 
prompted us to investigate the possible interaction 
of GRF with VIP receptors. Here, we show that 
GRF binds to VIP receptors in intestinal epithelial 
membranes and stimulates adenylate cyelase activi- 
ty. The effect of GRF is compared to that of 
secretin and PHI. It is analyzed both in rat and 
human intestine since marked species specificity 
has been previously noted for VIP receptors [9]. 
2. MATERIALS AND METHODS 
Synthetic human GRF-44-NH2 was prepared by 
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solid-phase techniques [lo] and was shown to have 
the full biological activity of native GRF [l]. PHI 
was isolated from porcine duodenum [2]. Synthetic 
porcine secretion was prepared as in [l 11. VIP was 
purified from porcine duodenum [3]. Membranes 
were prepared as in [12] from isolated rat small in- 
testinal epithelial cells [13] or isolated human col- 
onic epithelial crypts [14]. [‘251]VIP was prepared 
by the chloramine T method at a spec. act. of 
250 Ci/g [15]. It displays the same activity as 
native VIP in stimulating cyclic AMP accumula- 
tion in a cultured cell line (NT-29) which is highly 
and specifically sensitive to VIP [16]. Studies of 
binding of [‘251]VIP to membranes were conducted 
as in [ 171. Adenylate cyclase was assayed as in [ 121. 
3. RESULTS 
GRF inhibits competitively the specific binding 
of [‘251]VIP to epithelial cell membranes prepared 
from rat small intestine (fig. 1, top) and human col- 
on (fig.1, bottom). The inhibition is observed for 
GRF from lo-*-3 x 10s6 M (fig.l), half-maximal 
inhibition being obtained at a very similar GRF 
concentration in the two species; i.e., 280 nM. 
This contrasts markedly with the very different af- 
finity of the human and rat receptors for two other 
peptides; i.e., secretin and PHI (fig.1). Indeed, 
while half-maximal inhibition of [‘*‘I]VIP binding 
is obtained for 4.7 nM PHI and 31 nM secretin in 
rat, much higher concentrations of peptides are 
needed to obtain the same effect in man; e.g., 660 
and 2200 nM for PHI and secretin, respectively. 
These observations indicate that the great species 
specificity of VIP receptors with respect to PHI 
and secretin recognition does not concern the 
recognition of GRF. Neither does it concern the 
recognition of VIP itself since the affinity of VIP 
receptors for VIP is very similar in human and rat 
intestine (fig. 1). 
Fig.2 shows the dose-response of GRF, PHI, 
secretin and VIP in stimulating adenylate cyclase 
activity in rat (top) and human (bottom) intestinal 
membranes. As far as rat membranes are concern- 
ed, the order of potency of the different peptides 
in stimulating adenylate cyclase (fig.2, top) and in 
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Fig.1. Competitive inhibition of specific [1251]VIP 
binding to rat small intestinal epithelial membranes (top) 
and human colonic epithelial crypt membranes (bottom) 
by GRF, PHI, secretin and VIP. Results are expressed as 
the percentage of radioactivity specifically bound in the 
absence of added unlabeled peptide. Each point is the 
mean of 3 separate experiments; in each of the 
experiments determinations were made in quadruplicate. 
For the sake of clarity, standard errors are not indicated. 
Fig.2. Adenylate cyclase activity in rat small intestinal 
epithelial membranes (top) and human colonic epithelial 
crypt membranes (bottom) in response to increasing 
concentrations of GRF, PHI, secretin and VIP. Each 
point is the mean of 3 separate xperiments; in each of 
the experiments determinations were made in triplicate. 
For the sake of clarity, standard errors are not indicated. 
They are always below 9% of the mean values. They are always below 8% of the mean values. 
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Fig.3. Effect of increasing concentrations of GRF on the 
VIP-stimulated adenylate cyclase activity in rat small 
intestinal epithelial membranes. Each point is the 
mean f SE of 3 experiments: (a) GRF alone; (e) 
GRF + VIP (10m8 M), experimental values; (0) GRF + 
VIP (10e8 M), values expected if the effects of VIP and 
GRF were additive. 
inhibiting [1251]VIP binding (fig.1, top) is the 
same; i.e., VIP > PHI > secretin > GRF. 
However, while PHI and secretin appear to be full 
agonists of VIP, GRF behaves as a partial agonist 
with low intrinsic activity (fig.2, top). Indeed, at 
the maximal concentration tested (3 x 10m6 M), 
GRF completely inhibits [1251]VIP binding (fig. 1, 
top) but poorly stimulates adenylate cyclase activi- 
ty (fig.2, top). This observation suggests that GRF 
may antagonize the VIP effect in rat membranes. 
Indeed, as shown in fig.3, GRF antagonizes par- 
tially and in a dose-dependent fashion the VIP 
(lo-* M)-stimulated adenylate cyclase activity in 
rat intestinal membranes. In human membranes, 
GRF stimulates adenylate cyclase activity with a 
dose-response curve parallel to those observed 
with VIP, PHI and secretin (fig.2, bottom). 
However, it must be noticed that the orders of 
potency of the different peptides in stimulating 
adenylate cyclase activity (VIP > PHI > GRF > 
secretin) and in inhibiting the binding of [1251]VIP 
(VIP > GRF > PHI > secretin) are slightly 
different. 
4. DISCUSSION 
Here, we demonstrate that GRF is able to bind 
with a low affinity to VIP receptors in human and 
rat intestinal membranes. The concentrations of 
GRF needed to interact with VIP receptors and to 
stimulate adenylate cyclase through VIP receptors 
are high (1O-8-1O-5 M) in both species. This 
makes it very unlikely that GRF may elicit some 
physiological response through its interaction with 
VIP receptors. Indeed specific GRF actions as the 
stimulation of growth hormone release in vitro are 
observed for very low doses of peptide between 
1O-‘2-1O-g M [l]. Nevertheless, the interaction of 
GRF with VIP receptors provides new features to 
analyze the structure-function relationship of pep- 
tides of the VIP-secretin family. It is clear, both 
from these results and from those [18,19] and 
other laboratories [20] that an important species 
specificity exists in the ability of VIP receptors to 
discriminate the different peptides of this struc- 
tural family. While PHI and secretin have a much 
higher affinity for VIP receptors in rat than in 
man, the apparent affinity of GRF for VIP recep- 
tors appears to be low but very similar in the two 
species. This suggests that GRF does not contain 
the structural domain(s) involved in the determina- 
tion of species pecificity at the recognition site of 
VIP receptors. Despite its low affinity, GRF is able 
to completely inhibit the binding of [1251]VIP to 
human or rat receptors. Previous works have 
shown the importance of the N-terminal portion of 
VIP in the binding to receptors [18,21]. As far as 
this domain is concerned, GRF has 5 amino acids 
in common with VIP in the 10 first amino acids at 
the N-terminal while 4 other amino acids are in 
common in the remainder of the molecule. In par- 
ticular, the aspartate, phenylalanine and threonine 
residues, respectively, located in position 3, 6 and 
7, are identical in VIP, PHI, secretin and GRF and 
have been shown to be very important for binding 
to receptors [18]. Although these amino acids are 
certainly involved in the recognition of GRF by 
VIP receptors, the resemblances in the remainder 
of the peptide sequence cannot be neglected. In- 
deed, the entire length of the VIP sequence is pro- 
bably necessary to the process of binding, since 
VIP fragments have a very low affinity, if any, for 
the receptors [15]. The presence of a N-terminal 
tyrosine in GRF instead of a histidine in VIP and 
related peptides, is very probably a cause of the 
low affinity of GRF for VIP receptors. Indeed, 
modifications of this residue are associated with a 
marked loss of affinity of secretin analogues for 
VIP receptors [181. Such modification is even more 
drastic for the biological activity as shown with 
secretin analogues [22] and may be responsible for 
the low intrinsic activity of GRF to stimulate 
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adenylate cyclase activity, at least in rat intestinal 
membranes. It may also be the reason why GRF 
behaves as a partial VIP antagonist in rat mem- 
branes. Indeed, the modification of the N-terminal 
histidine of glucagon was similarly shown to result 
in the formation of a partial glucagon antagonist 
1231. 
In conclusion, this paper indicates that GRF 
binds to human and rat VIP receptors with a low 
affinity and may behave as a partial VIP 
agonist/antagonist in rat and as a VIP agonist in 
man. However, the concentrations of GRF needed 
to interact significantly with VIP receptors rule out 
the possibility that GRF may exert its physiological 
effect through VIP receptors. 
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